首页> 外文OA文献 >Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials

【2h】

Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials

机译：血清C-反应蛋白，白细胞介素-17a和白细胞介素-17F水平在银屑病关节炎中的血清素-17F水平的反应性：两期III，多中心，双盲，安慰剂对照试验的课程

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Stefan Siebert; Kristen Sweet; Bidisha Dasgupta; Kim Campbell; Iain B. McInnes; Matthew J. Loza;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials [J] . Siebert Stefan, Sweet Kristen, Dasgupta Bidisha, Arthritis & rheumatology. . 2019,第10期

机译：血清C-反应蛋白，白细胞介素-17a和白细胞介素-17F水平在银屑病关节炎中的反应性：两期III，多中心，双盲，安慰剂对照试验的课程
2. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial [J] . Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Journal of the American Academy of Dermatology . 2018,第2期

机译：白细胞介素17A和白细胞介素17F与牛皮癣患者的双胞胎素17F的双重中和：能够1，12周随机化，双盲，安慰剂控制相2B试验结果
3. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. [J] . Gottlieb A, Menter A, Mendelsohn A The Lancet . 2009,第9664期

机译：Ustekinumab，一种人白介素12/23单克隆抗体，用于银屑病关节炎：随机，双盲，安慰剂对照，交叉试验。
4. A randomized, double-blind, placebo-controlled phase II trial to examine the effect of polyphenon E on endogenous hormone levels [D] . Ling, Chen 2009

机译：一项随机，双盲，安慰剂对照的II期临床试验，用于研究多肽E对内源激素水平的影响
5. Extended report: Ixekizumab an interleukin-17A specific monoclonal antibody for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised double-blind placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 [O] . Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, -1

机译：扩展报告：Ixekizumab一种白介素17A特异性单克隆抗体用于治疗初生性活动性银屑病关节炎患者：24周随机双盲安慰剂对照和活性（阿达木单抗）对照期的结果SPIRIT-P1 III期试验
6. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 [O] . Mease, Philip J., van der Heijde, Désirée, Ritchlin, Christopher T., 2017

机译：Ixekizumab，一种白介素17A特异性单克隆抗体，用于治疗患有生物学性初发性银屑病关节炎的初生生物患者：III期24周随机，双盲，安慰剂对照和活性（阿达木单抗）对照期的结果试用SPIRIT-P1

Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials

著录项

相似文献

相关主题

期刊订阅